Abstract
Vascular risk factors and atherosclerosis are critically involved in dementia development of both vascular and Alzheimer’s type. However, the exact mechanisms linking atherosclerosis and the development of Alzheimer’s disease (AD) are still unknown. As platelet activation and adhesion on vascular wall is the first step of vascular inflammation and atherosclerosis, it appears tempting to hypothesize that platelets could be the link between vascular risk factors/ atherosclerosis and AD. In recent years, much work has been accomplished to elucidate the role of platelets in AD. The present review will summarize and highlight the latest findings of this research area and provide novel insight and understanding in the association between platelet activation and AD.
Keywords: Alzheimer’s disease, platelet activation, treatment targets, vascular risk factors, atherosclerosis, hyperlipidaemia, hypertension, type 2 diabetes, MCI, serotonin
Current Vascular Pharmacology
Title:Platelet Activation in Alzheimer’s Disease: From Pathophysiology to Clinical Value
Volume: 10 Issue: 5
Author(s): Christoph Laske, Kateryna Sopova and Konstantinos Stellos
Affiliation:
Keywords: Alzheimer’s disease, platelet activation, treatment targets, vascular risk factors, atherosclerosis, hyperlipidaemia, hypertension, type 2 diabetes, MCI, serotonin
Abstract: Vascular risk factors and atherosclerosis are critically involved in dementia development of both vascular and Alzheimer’s type. However, the exact mechanisms linking atherosclerosis and the development of Alzheimer’s disease (AD) are still unknown. As platelet activation and adhesion on vascular wall is the first step of vascular inflammation and atherosclerosis, it appears tempting to hypothesize that platelets could be the link between vascular risk factors/ atherosclerosis and AD. In recent years, much work has been accomplished to elucidate the role of platelets in AD. The present review will summarize and highlight the latest findings of this research area and provide novel insight and understanding in the association between platelet activation and AD.
Export Options
About this article
Cite this article as:
Laske Christoph, Sopova Kateryna and Stellos Konstantinos, Platelet Activation in Alzheimer’s Disease: From Pathophysiology to Clinical Value, Current Vascular Pharmacology 2012; 10 (5) . https://dx.doi.org/10.2174/157016112801784657
DOI https://dx.doi.org/10.2174/157016112801784657 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Spinal Microvascular Expression of PV-1 is Associated with Inflammation, Perivascular Astrocyte Loss, and Diminished EC Glucose Transport Potential in Acute SCI
Current Neurovascular Research Developments in HIV Neuropathogenesis
Current Pharmaceutical Design Decreased Platelet APP Isoform Ratios in Autosomal Dominant Alzheimer’s Disease: Baseline Data from a DIAN Cohort Subset
Current Alzheimer Research Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology Nature: A Substantial Source of Auspicious Substances with Acetylcholinesterase Inhibitory Action
Current Neuropharmacology Neuropeptides as Therapeutic Targets in Anxiety Disorders
Current Pharmaceutical Design A Comprehensive Review of the Genus Pyrola Herbs in Traditional Uses, Phytochemistry and Pharmacological Activities
Current Topics in Medicinal Chemistry Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk
Current Vascular Pharmacology Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol
CNS & Neurological Disorders - Drug Targets Low-Cost Anti-HIV Compounds: Potential Application for AIDS Therapy in Developing Countries
Current Pharmaceutical Design Allocentric to Egocentric Spatial Switching: Impairment in aMCI and Alzheimer's Disease Patients?
Current Alzheimer Research Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy Thrombomodulin – A New Target for Treating Stroke at the Crossroad of Coagulation and Inflammation
Current Medicinal Chemistry Pro-Inflammatory Cytokines IL-1β and TNF-α are not Associated with Plasma Homocysteine Concentration in Alzheimer’s Disease
Current Alzheimer Research Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Exploring Molecular Approaches in Amyotrophic Lateral Sclerosis: Drug Targets from Clinical and Pre-Clinical Findings
Current Molecular Pharmacology Targeting Parkinson’s - Tyrosine Hydroxylase and Oxidative Stress as Points of Interventions
CNS & Neurological Disorders - Drug Targets Filling the Gaps in the Aβ Cascade Hypothesis of Alzheimers Disease
Current Alzheimer Research Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Clinical Use of Neurophysiological Biomarkers and Self-Assessment Scales to Predict and Monitor Treatment Response for Psychotic and Affective Disorders
Current Pharmaceutical Design